LEXIVA (GW433908)

DRUG2 trials

Sponsors

GlaxoSmithKline, ViiV Healthcare

Conditions

HIV InfectionInfection, Human Immunodeficiency VirusInfection, Human Immunodeficiency Virus I

Phase 2

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

CompletedNCT00089583

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2004-07-31End: 2013-07-31Updated: 2017-03-07

Phase 3

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

CompletedNCT00085943

GlaxoSmithKlineHIV Infection, Infection, Human Immunodeficiency Virus

Start: 2004-05-31Target: 866Updated: 2011-05-16